16 October 2019
Visiongain has launched a new pharma report ‘’Moist Wound Dressings Market Report 2020-2030’’ by Product (Hydrocolloid Dressings, Foam Dressings, Alginate Dressings, Hydrogel Dressings, Film Dressings, Others), Application (Burn Wounds, Diabetic Ulcer, Pressure Ulcer, Surgical Wounds, Traumatic Wounds, Others), End Users (Homecare, Hospitals, Others), and Geography.
The global moist wound dressings market is anticipated to grow at a lucrative CAGR of 5.9% and anticipated to surpass USD 6.5 Billion by 2030.
A wound dressing is a method designed to safeguard wounds from microbial diseases, necrosis spread, and contamination. Dressing the wound by covering with a wet wound healing bandage enables to enhance wound healing. A wound is triggered by burns, accidents, cuts, scrapes, and causes injury to living tissue. Moist wound dressing offers a moist atmosphere that helps to heal injuries more quickly.
The growing incidence of acute and chronic wounds is driving the worldwide market for moist wound dressings. Acute injuries such as surgical injuries, traumatic injuries, chronic wounds, and pressure ulcers are increasing globally. Patients with first and second-degree burns, pressure ulcers, and diabetic ulcers are among the largest number of stays in hospitals in multiple healthcare environments worldwide. This increases demand for moist wound dressings as it guarantees quicker wound healing, improves autolytic debridement, and decreases the risk of wound infection.
Also, launching novel therapies such as electromagnetic treatment, electrical stimulation, nanotechnology, and using silver and other combination dressings is anticipated to boost market development. These advances guarantee better care for the wound and thus boost the acceptance of the product. The capacity of these dressings to control moisture at the wound site, which helps in tissue regeneration and decreased infection and pain, is one of the significant industry advances. Advanced products promote wound safety, protection against bacteria, thermal insulation, absorption of exudates, and more; thus, boosting the market growth.
Developing adequate reimbursement strategies is a growing trend in developed countries, resulting in a growing number of local market players. Increasing government initiatives for awareness of therapy in both advanced and developing nations serve as a significant chance for market leader having a global presence.
North America retains most of the market share followed by Europe and will continue to dominate in the future as a consequence of target population base presence and enhanced patient consciousness. Due to growing cases of chronic wounds in the region, such as diabetic foot and pressure ulcers, the market is projected to grow further. According to the CDC, in the United States, around 2.5 million patients suffer from pressure ulcers every year. Also, the factors contributing to the growth of the regional moist wound dressing market is the accessibility of products due to the existence of significant market players and their broad distribution network.
Growing demographics and economies are anticipated to stimulate market growth in the Asia Pacific region especially in emerging nations such as China, Japan, and India. Furthermore, advancements in wound care products and techniques, increasing technology acceptance and growing patient awareness are anticipated to offer fresh possibilities for regional growth.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global moist wound dressings market. Companies are also escalating their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the market.
The comprehensive market report features companies such as Acelity L.P., Inc., 3M, BSN Medical GmbH, Cardinal Health, B. Braun Melsungen AG, Coloplast A/S, Derma Sciences, Inc., Hollister Incorporated, Integra LifeSciences Holdings Corporation, ConvaTec, Inc., Laboratoires URGO, Medtronic, Medline Industries, Inc., Molnlycke Health Care AB, Smith & Nephew plc. and Systagenix among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020–2030 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.
03 December 2020
Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.
03 December 2020
Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.
03 December 2020
All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.